- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 133 more
Location Directory
Clinical trials in Cleveland, Ohio
This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
11328
Shown on this page
12
Current sort
Recently updated
Location scope
Cleveland, OH
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 133–144 of 11,328 matching trials in Cleveland, OH.
Live ClinicalTrials.gov results.
Institutions in Cleveland
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Focal Onset Seizures
- Interventions
- XEN1101, Placebo
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Downey, California • Los Angeles, California + 16 more
- Conditions
- Polycythemia Vera (PV)
- Interventions
- DISC-3405
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 11 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
- Interventions
- furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
- Drug
- Lead sponsor
- ArriVent BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 69
- States / cities
- Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more
- Conditions
- Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
- Interventions
- Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
- Procedure · Radiation · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 344
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 265 more
- Conditions
- Aortic Valve Stenosis
- Interventions
- Medtronic Transcatheter Aortic Valve Replacement Systems, Surgical Aortic Valve Replacement (SAVR)
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 53 more
- Conditions
- Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
- Interventions
- Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 265
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 199 more
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
- Interventions
- Casdatifan, Cabozantinib, Placebo
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Solid Tumors
- Interventions
- casdatifan, Cabozantinib, Zimberelimab, Ipilimumab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • San Diego, California • Santa Monica, California + 13 more
- Conditions
- Low Grade Serous Ovarian Cancer
- Interventions
- avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Interventions
- Vutrisiran, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 17
- States / cities
- La Mesa, California • Los Angeles, California • Stanford, California + 13 more
- Conditions
- Neoplasms
- Interventions
- Gene-modified (GM) T cell therapy
- Genetic
- Lead sponsor
- Celgene
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2043
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more